Safety Data Sheet (SDS) Development and Compliance Support

The contract requires the development, submission, and ongoing periodic updates of Safety Data Sheets for Gabapentin capsules to ensure full compliance with OSHA’s Hazard Communication Standard and DFARS regulations. The work involves creating accurate, standardized documentation that communicates chemical hazards, handling instructions, emergency measures, and regulatory information, tailored specifically to the formulation and use of Gabapentin capsules. All SDS documents must meet federal requirements for clarity, consistency, and legal defensibility, with updates triggered by regulatory changes, new scientific data, or product modifications. The undertaking is structured as a subcontract under the Department of Defense’s Medical Supply Chain Pharm FSA, with performance based at FPO, ZIP 96672. The solicitation, issued under NAICS code 541690 for other scientific and technical consulting services, was posted on August 3, 2026, with proposals due by August 10, 2026. While no set-aside designation is specified, the obligation is tied to DoD supply chain requirements, emphasizing the need for strict adherence to defense contracting standards alongside general safety and regulatory protocols. Continuous compliance is mandatory, with the contractor expected to maintain active oversight and timely revisions throughout the agreement term.